 saxagliptin |
| Onglyza |
Pharmaceutical
company:
Bristol-Myers Squibb
www.onglyza.com |
Pharmacologic classification: dipeptidyl peptidase-4 enzyme inhibitor
Therapeutic classification: antidiabetic drug
Pregnancy risk category: B
AVAILABLE FORMS
Tablets: 2.5, 5 mg
INDICATIONS AND DOSAGES
Adjunct to diet and exercise to improve glycemic control in type 2 diabetes—
Adults: 2.5 to 5 mg P.O. once daily.
CONTRAINDICATIONS AND CAUTIONS
Use cautiously in patients taking secretagogues, such as sulfonylureas, because of increased risk of hypoglycemia.
INTERACTIONS
Drug-drug.
Strong CYP3A4/5 inhibitors (ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin): May increase saxagliptin levels. Reduce dose to 2.5 mg P.O. daily.
ADVERSE REACTIONS
CNS: headache, peripheral edema.
EENT: sinusitis.
GI: abdominal pain, gastroenteritis, vomiting.
GU: UTI.
Metabolic: hypoglycemia.
Respiratory: upper respiratory tract infection.
Skin: urticaria.
Other: facial edema.
Reactions may be common, uncommon, life-threatening,
or COMMON AND LIFE-THREATENING.
|
